ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
건막염 치료제 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 12억 7,000만 달러에서 2026년에는 13억 7,000만 달러에 이르고, CAGR 7.7%로 성장할 전망입니다. 지난 수년간의 성장에는 직업적 손상 증가, 비스테로이드성 항염증제(NSAIDs)의 광범위한 사용, 정형외과 의료시설의 확충, 고령화에 따른 근골격계 문제, 외래 치료의 채택 증가 등이 요인으로 작용한 것으로 보입니다.
건막염 치료제 시장 규모는 향후 몇 년간 견실한 성장이 전망됩니다. 2030년에는 18억 4,000만 달러에 이르고, CAGR은 7.6%를 나타낼 전망입니다. 예측 기간 동안의 성장 요인으로는 직장 관련 부상 증가, 스포츠 참여자 증가, 저침습적 치료 확대, 진통제 수요 증가, 외래 정형외과 의료 확대 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 반복적 스트레스 손상 발생률 증가, 항염증제 사용 증가, 주사용 코르티코스테로이드 사용 확대, 보존적 근골격계 치료 확대, 조기 통증 관리에 대한 집중 강화 등을 꼽을 수 있습니다.
스포츠 부상 발생률 증가는 향후 몇 년 동안 건염 치료제 시장의 확대를 촉진할 것으로 예측됩니다. 스포츠 부상은 운동이나 경기 중 발생하는 신체적 손상으로, 경미한 염좌나 근육 이탈부터 심각한 골절이나 탈구까지 다양한 부상을 뜻합니다. 이러한 부상은 과도한 사용, 부적절한 기술, 불충분한 준비 운동 및 스트레칭, 다른 선수나 물체와의 충돌 등 여러 가지 요인에 의해 발생합니다. 건염 치료제는 힘줄의 염증을 줄이고 통증을 완화하여 스포츠 부상 관리에 사용되며, 회복을 촉진하고 운동성을 향상시키는데 기여합니다. 예를 들어, 2023년 11월 영국의 보험 중개회사인 하우덴 그룹 홀딩스(Howden Group Holdings)는 2022년 10월부터 2023년 1월까지 잉글랜드 프리미어리그에서 발목 부상의 심각성이 170% 증가했다고 보고했습니다. 또한 FIFA 카타르 월드컵 2022가 끝난 후 종아리와 정강이 부상은 200%, 햄스트링 부상은 130% 증가했습니다. 따라서 스포츠 부상 증가 추세는 건염 치료제 분야의 발전을 촉진하고 있습니다.
향후 몇 년 동안 의료비 지출 증가가 건염 치료제 시장의 성장을 견인할 것으로 예측됩니다. 보건의료 지출은 국민의 건강 유지 및 증진을 목적으로 의료품 및 서비스에 할당되는 총 자금을 의미합니다. 고령화가 진행됨에 따라 더 빈번한 의료 서비스와 장기적인 건강 서비스가 필요하기 때문에 의료비는 증가 추세에 있습니다. 의료비 지출 증가는 접근성 확대, 진단 및 치료 제공 강화, 연구 및 치료 정책 지원을 통해 건염 치료제의 도입과 효과를 촉진할 수 있습니다. 예를 들어, 영국 정부 기관인 국가통계청(Office for National Statistics)에 따르면, 2025년 4월 기준 2023년부터 2024년까지 헬스케어 총액은 명목 기준으로 6.5% 증가했으며, 인플레이션 조정 후 실질 기준으로는 2.4% 증가했습니다. 이처럼 의료비 지출 증가가 건염 치료제 시장의 성장을 견인하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업 및 혁신 기업
제38장 세계 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병(M&A)
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
LSH
영문 목차
영문목차
Tenosynovitis drugs are medications designed to alleviate inflammation, pain, and swelling in the tendon sheath resulting from infections, overuse, or autoimmune disorders. Treatment options include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and antibiotics in cases of infection. In more severe instances, disease-modifying antirheumatic drugs (DMARDs) or biologics may be prescribed for chronic inflammatory forms.
The primary drug categories for tenosynovitis include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, antibiotics, and other types of medications. NSAIDs are designed to alleviate pain and inflammation without using steroids. They help manage tenosynovitis by reducing symptoms such as swelling and discomfort. Conditions treated include De Quervain tenosynovitis, stenosing tenosynovitis, trigger finger, and other related conditions. These drugs are administered orally, through injections, or topically and are made available via hospital pharmacies, retail pharmacies, and online pharmacies.
Tariffs have raised the price of imported anti inflammatory and corticosteroid APIs used in oral and injectable tenosynovitis drug formulations. These impacts are most pronounced in North America and Europe, where reliance on cross border pharmaceutical sourcing remains high. Rising tariff related expenses have influenced manufacturing costs, pricing strategies, and procurement planning for musculoskeletal therapies. This has affected treatment affordability and supply availability in hospital and outpatient settings. Positively, tariffs are supporting domestic drug formulation capacity, expanded local manufacturing investment, and stronger regional pharmaceutical supply chains over the long term.
The tenosynovitis drugs market research report is one of a series of new reports from The Business Research Company that provides tenosynovitis drugs market statistics, including tenosynovitis drugs industry global market size, regional shares, competitors with a tenosynovitis drugs market share, detailed tenosynovitis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the tenosynovitis drugs industry. This tenosynovitis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The tenosynovitis drugs market size has grown strongly in recent years. It will grow from $1.27 billion in 2025 to $1.37 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to growth in occupational injuries, widespread nsaid usage, expansion of orthopedic care facilities, aging population musculoskeletal issues, increased outpatient treatment adoption.
The tenosynovitis drugs market size is expected to see strong growth in the next few years. It will grow to $1.84 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to rising workplace-related injuries, increasing sports participation, growth in minimally invasive treatments, rising demand for pain relief drugs, expansion of outpatient orthopedic care. Major trends in the forecast period include rising incidence of repetitive strain injuries, increased use of anti-inflammatory therapies, growing adoption of injectable corticosteroids, expansion of conservative musculoskeletal treatments, increased focus on early pain management.
The rising occurrence of sports injuries is expected to fuel the expansion of the tenosynovitis drugs sector in the coming years. Sports injuries are physical harms sustained during athletic activities or exercise, ranging from minor sprains and strains to more serious fractures or dislocations. These injuries result from multiple factors, including overuse, incorrect technique, inadequate warm-up or stretching, and collisions with other players or objects. Tenosynovitis drugs are employed in managing sports injuries by reducing tendon inflammation and alleviating pain, facilitating quicker recovery and enhanced mobility. For example, in November 2023, Howden Group Holdings Ltd, a UK-based insurance intermediary, reported that the severity of ankle injuries in the English Premier League increased by 170% between October 2022 and January 2023, with calf and shin injuries rising by 200% and hamstring injuries by 130%, following the FIFA World Cup Qatar 2022. Hence, the growing prevalence of sports injuries is driving the development of the tenosynovitis drugs sector.
The increasing healthcare expenditure is expected to drive the growth of the tenosynovitis drugs market in the coming years. Healthcare expenditure refers to the total financial resources allocated to medical goods and services aimed at maintaining and improving population health. Healthcare spending is rising as an aging population demands more frequent medical attention and long-term health services. Higher healthcare expenditure facilitates the adoption and effectiveness of tenosynovitis drugs by expanding access, enhancing diagnosis and treatment delivery, and supporting research and care initiatives. For example, in April 2025, according to the Office for National Statistics, a UK-based government department, total healthcare spending rose by 6.5% in nominal terms between 2023 and 2024, and by 2.4% in real terms after adjusting for inflation. Thus, the increasing healthcare expenditure is propelling the growth of the tenosynovitis drugs market.
Major companies operating in the tenosynovitis drugs sector are emphasizing advanced drug formulations, such as delayed-release NSAID preparations, to improve gastrointestinal tolerability and targeted anti-inflammatory effects. Delayed-release NSAID preparation refers to a pharmaceutical form of a non-steroidal anti-inflammatory drug (NSAID), such as naproxen, engineered to release the active ingredient at a later stage in the gastrointestinal tract. For example, in July 2024, ANI Pharmaceuticals Inc., a US-based pharmaceutical firm, announced that it had obtained U.S. Food and Drug Administration (FDA) approval for its abbreviated new drug application (ANDA) and had launched Naproxen delayed-release tablets, USP. This medicine was introduced as the generic equivalent of the reference listed drug (RLD), EC-Naprosyn, providing the same therapeutic benefits at a more cost-effective price. The delayed-release formulation was designed to deliver extended pain relief while minimizing gastric irritation, making it an effective treatment for inflammatory conditions such as arthritis, tendonitis, and tenosynovitis.
Major companies operating in the tenosynovitis drugs market are Pfizer Inc., Roche Holding AG, Bayer AG, Sanofi S.A., AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Cipla Limited, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Endo International plc, Lupin Limited, Mallinckrodt Pharmaceuticals, Zydus Cadila Healthcare, AdvaCare Pharma.
North America was the largest region in the tenosynovitis drugs market in 2025. The regions covered in the tenosynovitis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the tenosynovitis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The tenosynovitis drugs market includes revenues earned by prescription medications, over-the-counter (OTC) products, biologics and disease-modifying drugs, topical treatments, injections, and infusions. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Tenosynovitis Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses tenosynovitis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for tenosynovitis drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The tenosynovitis drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Drug Type: Nonsteroidal Anti-Inflammatory Drugs (NSAIDS); Corticosteroids; Antibiotics; Other Drug Types
2) By Indication: De Quervain Tenosynovitis; Stenosing Tenosynovitis; Trigger Finger; Other Indications
3) By Route Of Administration: Oral; Injectable; Topical
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen; Naproxen; Diclofenac; Celecoxib
2) By Corticosteroids: Prednisone; Methylprednisolone; Dexamethasone; Triamcinolone
3) By Antibiotics: Penicillins; Cephalosporins; Fluoroquinolones; Macrolides
4) By Other Drug Types: Disease-Modifying Anti-Rheumatic Drugs (DMARDs); Biologics; Analgesics
Companies Mentioned: Pfizer Inc.; Roche Holding AG; Bayer AG; Sanofi S.A.; AstraZeneca plc; GSK plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Amgen Inc.; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Perrigo Company plc; Cipla Limited; Dr. Reddy's Laboratories Ltd.; Aurobindo Pharma Limited; Endo International plc; Lupin Limited; Mallinckrodt Pharmaceuticals; Zydus Cadila Healthcare; AdvaCare Pharma.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.2.1 Rising Incidence Of Repetitive Strain Injuries
4.2.2 Increased Use Of Anti-Inflammatory Therapies
4.2.3 Growing Adoption Of Injectable Corticosteroids
4.2.4 Expansion Of Conservative Musculoskeletal Treatments
4.2.5 Increased Focus On Early Pain Management
5. Tenosynovitis Drugs Market Analysis Of End Use Industries
5.1 Orthopedic Hospitals
5.2 Sports Medicine Clinics
5.3 General Hospitals
5.4 Rehabilitation Centers
5.5 Homecare Patients
6. Tenosynovitis Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Tenosynovitis Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Tenosynovitis Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Tenosynovitis Drugs Market Size, Comparisons And Growth Rate Analysis
7.3. Global Tenosynovitis Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Tenosynovitis Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Tenosynovitis Drugs Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Tenosynovitis Drugs Market Segmentation
9.1. Global Tenosynovitis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Corticosteroids, Antibiotics, Other Drug Types
9.2. Global Tenosynovitis Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
De Quervain Tenosynovitis, Stenosing Tenosynovitis, Trigger Finger, Other Indications
9.3. Global Tenosynovitis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Oral, Injectable, Topical
9.4. Global Tenosynovitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Tenosynovitis Drugs Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Tenosynovitis Drugs Market
12.1. China Tenosynovitis Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Tenosynovitis Drugs Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Tenosynovitis Drugs Market
13.1. India Tenosynovitis Drugs Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Tenosynovitis Drugs Market
14.1. Japan Tenosynovitis Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Tenosynovitis Drugs Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Tenosynovitis Drugs Market
15.1. Australia Tenosynovitis Drugs Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Tenosynovitis Drugs Market
16.1. Indonesia Tenosynovitis Drugs Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Tenosynovitis Drugs Market
17.1. South Korea Tenosynovitis Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Tenosynovitis Drugs Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. Taiwan Tenosynovitis Drugs Market
18.1. Taiwan Tenosynovitis Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Tenosynovitis Drugs Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Tenosynovitis Drugs Market
19.1. South East Asia Tenosynovitis Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Tenosynovitis Drugs Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Tenosynovitis Drugs Market
20.1. Western Europe Tenosynovitis Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Tenosynovitis Drugs Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Tenosynovitis Drugs Market
21.1. UK Tenosynovitis Drugs Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Tenosynovitis Drugs Market
22.1. Germany Tenosynovitis Drugs Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Tenosynovitis Drugs Market
23.1. France Tenosynovitis Drugs Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Tenosynovitis Drugs Market
24.1. Italy Tenosynovitis Drugs Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Tenosynovitis Drugs Market
25.1. Spain Tenosynovitis Drugs Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Tenosynovitis Drugs Market
26.1. Eastern Europe Tenosynovitis Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Tenosynovitis Drugs Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Tenosynovitis Drugs Market
27.1. Russia Tenosynovitis Drugs Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Tenosynovitis Drugs Market
28.1. North America Tenosynovitis Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Tenosynovitis Drugs Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Tenosynovitis Drugs Market
29.1. USA Tenosynovitis Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Tenosynovitis Drugs Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
30. Canada Tenosynovitis Drugs Market
30.1. Canada Tenosynovitis Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Tenosynovitis Drugs Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Tenosynovitis Drugs Market
31.1. South America Tenosynovitis Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Tenosynovitis Drugs Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Tenosynovitis Drugs Market
32.1. Brazil Tenosynovitis Drugs Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Tenosynovitis Drugs Market
33.1. Middle East Tenosynovitis Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Tenosynovitis Drugs Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Tenosynovitis Drugs Market
34.1. Africa Tenosynovitis Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Tenosynovitis Drugs Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Tenosynovitis Drugs Market Regulatory and Investment Landscape
36. Tenosynovitis Drugs Market Competitive Landscape And Company Profiles
36.1. Tenosynovitis Drugs Market Competitive Landscape And Market Share 2024
36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Tenosynovitis Drugs Market - Company Scoring Matrix
36.2.1. Market Revenues
36.2.2. Product Innovation Score
36.2.3. Brand Recognition
36.3. Tenosynovitis Drugs Market Company Profiles
36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
36.3.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
36.3.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
36.3.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
36.3.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
37. Tenosynovitis Drugs Market Other Major And Innovative Companies
GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Cipla Limited, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Endo International plc, Lupin Limited, Mallinckrodt Pharmaceuticals, Zydus Cadila Healthcare, AdvaCare Pharma
38. Global Tenosynovitis Drugs Market Competitive Benchmarking And Dashboard
39. Key Mergers And Acquisitions In The Tenosynovitis Drugs Market
40. Tenosynovitis Drugs Market High Potential Countries, Segments and Strategies
40.1 Tenosynovitis Drugs Market In 2030 - Countries Offering Most New Opportunities
40.2 Tenosynovitis Drugs Market In 2030 - Segments Offering Most New Opportunities
40.3 Tenosynovitis Drugs Market In 2030 - Growth Strategies
